Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
4801
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4802
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4803
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4804
Methodology.
Published 2024“…Upon binding of lactate YFP and CFP move farther apart, the intensity of YFP fluorescence decreases while that of CFP increases. This leads to a decrease in the YFP/CFP FRET ratio. …”
-
4805
-
4806
-
4807
-
4808
-
4809
-
4810
-
4811
-
4812
-
4813
-
4814
-
4815
-
4816
-
4817
-
4818
-
4819
-
4820